Physician profile
Dann J Fredrickson
NPI 1215934203
$10,862.06
in general payments reported to CMS, 2019-2025
49 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $1,008 · 2021: $1,147 · 2022: $1,568 · 2023: $1,563 · 2024: $1,904 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,747.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,453.75 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $909.03 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $877.51 | 2019-2025 | |
| Pfizer INC. | $778.20 | 2019-2025 | |
| Lilly USA, LLC | $769.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $725.61 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $600.51 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $349.89 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.89 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $321.85 | 2019-2022 | |
| Allergan, INC. | $197.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $136.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $127.79 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $126.54 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dann Fredrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.